Wixela Inhub: Dosing Performance In Vitro and Inhaled Flow Rates in Healthy Subjects and Patients Compared with Advair Diskus

Background: Wixela™ Inhub™ is a fluticasone propionate/salmeterol dry powder inhaler developed as a generic equivalent of Advair Diskus(®) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Wixela Inhub and Advair Diskus are comparable in terms of functionality, user inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Andrew, Parker, James, Berry, Mark, Wallace, Róisín, Ward, Jon, Allan, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757596/
https://www.ncbi.nlm.nih.gov/pubmed/32429788
http://dx.doi.org/10.1089/jamp.2019.1584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757596/
https://www.ncbi.nlm.nih.gov/pubmed/32429788
http://dx.doi.org/10.1089/jamp.2019.1584

Ejemplares similares